• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Covid-19: What is the evidence for the antiviral Paxlovid?

作者信息

Extance Andy

机构信息

Exeter.

出版信息

BMJ. 2022 Apr 27;377:o1037. doi: 10.1136/bmj.o1037.

DOI:10.1136/bmj.o1037
PMID:35477536
Abstract
摘要

相似文献

1
Covid-19: What is the evidence for the antiviral Paxlovid?新冠病毒：抗新冠病毒药物帕罗韦德的证据有哪些？
BMJ. 2022 Apr 27;377:o1037. doi: 10.1136/bmj.o1037.
2
COVID-19 update: Prescription of Paxlovid by pharmacists.新冠疫情最新情况：药剂师开具帕罗韦德处方。
Med Lett Drugs Ther. 2022 Aug 8;64(1656):e124.
3
Paxlovid for treatment of COVID-19.用于治疗新冠病毒病的帕罗韦德
Med Lett Drugs Ther. 2022 Jan 24;64(1642):9-10.
4
Exploring Paxlovid Efficacy in COVID-19 Patients with MAFLD: Insights from a Single-Center Prospective Cohort Study.探讨 MAFLD 患者应用 Paxlovid 的疗效：一项单中心前瞻性队列研究的启示。
Viruses. 2024 Jan 12;16(1):112. doi: 10.3390/v16010112.
5
Public Health Impact of Paxlovid as Treatment for COVID-19, United States.辉瑞公司研发的新冠病毒治疗药物 Paxlovid 对公共卫生的影响，美国。
Emerg Infect Dis. 2024 Feb;30(2):262-269. doi: 10.3201/eid3002.230835. Epub 2024 Jan 5.
6
Paxlovid Is Effective but Underused-Here's What the Latest Research Says About Rebound and More.帕罗韦德有效但未得到充分利用——以下是关于反弹及更多情况的最新研究内容。
JAMA. 2024 Feb 20;331(7):548-551. doi: 10.1001/jama.2023.28254.
7
Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences.帕克洛维德药物说明书中列出的相互作用，根据风险、药物类别和后果进行分类。
Rev Esp Quimioter. 2022 Aug;35(4):357-361. doi: 10.37201/req/054.2022. Epub 2022 Jul 13.
8
The future of Paxlovid for COVID-19.帕罗韦德用于治疗新冠肺炎的未来。
Lancet Respir Med. 2022 Jul;10(7):e68. doi: 10.1016/S2213-2600(22)00192-8. Epub 2022 May 24.
9
Three more points about Paxlovid for covid-19.关于用于治疗新冠的帕罗韦德（Paxlovid），还有三点要讲。
BMJ. 2022 Jun 7;377:o1397. doi: 10.1136/bmj.o1397.
10
Covid-19: NICE plans to expand Paxlovid eligibility to 1.4 million more people.新冠疫情：英国国家卫生与临床优化研究所计划将帕罗韦德的适用人群再扩大140万。
BMJ. 2024 Jan 11;384:q59. doi: 10.1136/bmj.q59.

引用本文的文献

1
Data mining of adverse drug event signals with Nirmatrelvir/Ritonavir from FAERS.利用美国食品药品监督管理局不良事件报告系统（FAERS）对奈玛特韦/利托那韦的药物不良事件信号进行数据挖掘。
PLoS One. 2024 Dec 31;19(12):e0316573. doi: 10.1371/journal.pone.0316573. eCollection 2024.
2
Preclinical and Clinical Investigations of Potential Drugs and Vaccines for COVID-19 Therapy: A Comprehensive Review With Recent Update.COVID-19治疗潜在药物和疫苗的临床前与临床研究：近期更新的综合综述
Clin Pathol. 2024 Jul 26;17:2632010X241263054. doi: 10.1177/2632010X241263054. eCollection 2024 Jan-Dec.
3
Nirmatrelvir and ritonavir for inpatients with severe or critical COVID-19 beyond five days of symptom onset: a propensity score-matched, multicenter, retrospective cohort study.
奈玛特韦片/利托那韦片用于发病 5 天以上的重症或危重症 COVID-19 住院患者：一项倾向评分匹配、多中心、回顾性队列研究。
BMC Infect Dis. 2024 Jun 18;24(1):597. doi: 10.1186/s12879-024-09150-1.
4
Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir-A Literature Review.奈玛特韦/利托那韦片的临床疗效评价：文献综述。
Adv Respir Med. 2024 Jan 18;92(1):66-76. doi: 10.3390/arm92010009.
5
Comparison of Azvudine and Nirmatrelvir/Ritonavir and Combined Use in Patients with COVID-19.阿兹夫定与奈玛特韦/利托那韦对比及联合应用于新型冠状病毒肺炎患者的研究
Infect Drug Resist. 2023 Dec 22;16:7797-7808. doi: 10.2147/IDR.S433186. eCollection 2023.
6
Effectiveness of molnupiravir vs nirmatrelvir-ritonavir in non-hospitalised and hospitalised patients with COVID-19: a target trial emulation study.莫努匹韦与奈玛特韦-利托那韦治疗非住院和住院COVID-19患者的疗效：一项目标试验模拟研究
EClinicalMedicine. 2023 Sep 20;64:102225. doi: 10.1016/j.eclinm.2023.102225. eCollection 2023 Oct.
7
Identification of new drugs to counteract anti-spike IgG-induced hyperinflammation in severe COVID-19.鉴定对抗严重 COVID-19 中抗刺突 IgG 诱导的过度炎症的新型药物。
Life Sci Alliance. 2023 Sep 12;6(11). doi: 10.26508/lsa.202302106. Print 2023 Nov.
8
Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease.新型抗病毒药物早期治疗 COVID-19 的平台适应性试验：一项针对社区中新型抗病毒药物治疗 COVID-19 的随机、对照、开放标签、适应性平台试验的方案，针对有发展为更严重疾病风险增加的人群。
BMJ Open. 2023 Aug 7;13(8):e069176. doi: 10.1136/bmjopen-2022-069176.
9
Severe COVID-19: Drugs and Clinical Trials.重症新型冠状病毒肺炎：药物与临床试验
J Clin Med. 2023 Apr 16;12(8):2893. doi: 10.3390/jcm12082893.
10
Acute Encephalopathy Due to Polypharmacy Interactions With the Use of Paxlovid: A Case Report.因与帕罗韦德联合用药导致的多药相互作用引起的急性脑病：一例报告
Cureus. 2023 Mar 22;15(3):e36535. doi: 10.7759/cureus.36535. eCollection 2023 Mar.